These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7030887)

  • 21. Effects of some hypocholesterolemic agents on hepatic ulrastructure and microbody enzymes.
    Hruban Z; Mochizuki Y; Goto M; Slesers A; Chou SH
    Lab Invest; 1974 Apr; 30(4):474-85. PubMed ID: 4150963
    [No Abstract]   [Full Text] [Related]  

  • 22. [The mechanism of action of hypolipidemic drugs].
    Scheen AJ
    Rev Med Liege; 1997 Jun; 52(6):445-6. PubMed ID: 9289779
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
    Makowska JM; Bonner FW; Gibson GG
    Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate.
    Reddy JK; Krishnakantha TP
    Science; 1975 Nov; 190(4216):787-9. PubMed ID: 1198095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Peroxisomes and hypolipidemic agents ].
    Heller F; Pourbaix S
    Sem Hop; 1982 Jul; 58(28-29):1712-7. PubMed ID: 6289453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the response of Sprague-Dawley and Lewis rats to bezafibrate: the hypolipidemic effect and the induction of peroxisomal enzymes.
    Pill J; Völkl A; Hartig F; Fahimi HD
    Arch Toxicol; 1992; 66(5):327-33. PubMed ID: 1610295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of perfluorooctanoic acid--induced peroxisomal enzyme activities and hepatocellular growth by adrenal hormones.
    Thottassery J; Winberg L; Youssef J; Cunningham M; Badr M
    Hepatology; 1992 Feb; 15(2):316-22. PubMed ID: 1735536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid, and Wy-14,643) on hepatic peroxisomes and peroxisome-associated enzymes.
    Moody DE; Reddy JK
    Am J Pathol; 1978 Feb; 90(2):435-46. PubMed ID: 623209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid.
    Wilson MW; Lay LT; Chow CK; Tai HH; Robertson LW; Glauert HP
    Arch Toxicol; 1995; 69(7):491-7. PubMed ID: 8526745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypolipidaemic properties of a new tetralin derivative (CIBA 13,437-Su).
    Hess R; Bencze WL
    Experientia; 1968 May; 24(5):418-9. PubMed ID: 5674960
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens.
    Williams GM; Perrone C
    Ann N Y Acad Sci; 1996 Dec; 804():554-72. PubMed ID: 8993573
    [No Abstract]   [Full Text] [Related]  

  • 32. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
    Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
    Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hypolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella.
    Glauert HP; Reddy JK; Kennan WS; Sattler GL; Rao VS; Pitot HC
    Cancer Lett; 1984 Sep; 24(2):147-56. PubMed ID: 6383598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential role of chemically induced hyperplasia in the carcinogenic activity of the hypolipidemic carcinogens.
    Butterworth BE; Loury DJ; Smith-Oliver T; Cattley RC
    Toxicol Ind Health; 1987 Jun; 3(2):129-49. PubMed ID: 3303446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Method for determining whether the number of hepatocytes in rat liver is increased after treatment with the peroxisome proliferator gemfibrozil.
    Carthew P; Maronpot RR; Foley JF; Edwards RE; Nolan BM
    J Appl Toxicol; 1997; 17(1):47-51. PubMed ID: 9048227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells.
    Voskoboinik I; Drew R; Ahokas JT
    Chem Biol Interact; 1997 Jul; 105(2):81-97. PubMed ID: 9251722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peroxisome proliferators: paradigms and prospects.
    Gibson GG
    Toxicol Lett; 1993 May; 68(1-2):193-201. PubMed ID: 8390728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators; di(2-ethylhexyl) phthalate, aluminium clofibrate and simfibrate.
    Takagi A; Sai K; Umemura T; Hasegawa R; Kurokawa Y
    Cancer Lett; 1990 Aug; 53(1):33-8. PubMed ID: 2397479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response.
    Hennuyer N; Poulain P; Madsen L; Berge RK; Houdebine LM; Branellec D; Fruchart JC; Fiévet C; Duverger N; Staels B
    Circulation; 1999 May; 99(18):2445-51. PubMed ID: 10318668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.